Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease
Abstract Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients...
Gespeichert in:
| Veröffentlicht in: | Open forum infectious diseases 2017, Vol.4 (4), p.ofx202-ofx202 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | ofx202 |
|---|---|
| container_issue | 4 |
| container_start_page | ofx202 |
| container_title | Open forum infectious diseases |
| container_volume | 4 |
| creator | Zimmerman, Ofer Rösler, Berenice Zerbe, Christa S Rosen, Lindsey B Hsu, Amy P Uzel, Gulbu Freeman, Alexandra F Sampaio, Elizabeth P Rosenzwieg, Sergio D Kuehn, Hye Sun Kim, Tiffany Brooks, Kristina M Kumar, Parag Wang, Xiaowen Netea, Mihai G van de Veerdonk, Frank L Holland, Steven M |
| description | Abstract
Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections. |
| doi_str_mv | 10.1093/ofid/ofx202 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_TOX</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5714179</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/ofid/ofx202</oup_id><sourcerecordid>1975596745</sourcerecordid><originalsourceid>FETCH-LOGICAL-c478t-36a2b9d5e4b6022d065206f01610029d952b8e4d56b84c5183f90aba42c9a3453</originalsourceid><addsrcrecordid>eNp9kcFLwzAUxoMobsydvEtOIkg1SZu0uQhjuikMBts8hzRNZ7RLZtOO-d_b2Tnmxct7D74f33u8D4BLjO4w4uG9y03WlC1B5AR0SUiSIOE0Pj2aO6Dv_TtCCGNEUczPQYdwQhhmSRdMZ8Z_eOhyOKu3rjCVsSaFxsL5YrDAcCyNDVwejGqrKuNsMPDeKSMrncG53uhSw0ZaygI-Gq-l1xfgLJeF1_1974HX0dNi-BxMpuOX4WASqChOqiBkkqQ8ozpKGSIkQ4wSxHKEGUaI8IxTkiY6yihLk0hRnIQ5RzKVEVFchhENe-Ch9V3X6UpnStuqlIVYl2Ylyy_hpBF_FWvexNJtBI1xhGPeGNzsDUr3WWtfiZXxSheFtNrVXmAeU8pZ_LPrtkVV6bwvdX5Yg5HYpSB2KYg2hYa-Or7swP7-vAGuW8DV63-dvgFqNJBi</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1975596745</pqid></control><display><type>article</type><title>Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease</title><source>Oxford Journals Open Access Collection</source><creator>Zimmerman, Ofer ; Rösler, Berenice ; Zerbe, Christa S ; Rosen, Lindsey B ; Hsu, Amy P ; Uzel, Gulbu ; Freeman, Alexandra F ; Sampaio, Elizabeth P ; Rosenzwieg, Sergio D ; Kuehn, Hye Sun ; Kim, Tiffany ; Brooks, Kristina M ; Kumar, Parag ; Wang, Xiaowen ; Netea, Mihai G ; van de Veerdonk, Frank L ; Holland, Steven M</creator><creatorcontrib>Zimmerman, Ofer ; Rösler, Berenice ; Zerbe, Christa S ; Rosen, Lindsey B ; Hsu, Amy P ; Uzel, Gulbu ; Freeman, Alexandra F ; Sampaio, Elizabeth P ; Rosenzwieg, Sergio D ; Kuehn, Hye Sun ; Kim, Tiffany ; Brooks, Kristina M ; Kumar, Parag ; Wang, Xiaowen ; Netea, Mihai G ; van de Veerdonk, Frank L ; Holland, Steven M</creatorcontrib><description>Abstract
Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofx202</identifier><identifier>PMID: 29226168</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Brief Report</subject><ispartof>Open forum infectious diseases, 2017, Vol.4 (4), p.ofx202-ofx202</ispartof><rights>Published by Oxford University Press on behalf of Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c478t-36a2b9d5e4b6022d065206f01610029d952b8e4d56b84c5183f90aba42c9a3453</citedby><cites>FETCH-LOGICAL-c478t-36a2b9d5e4b6022d065206f01610029d952b8e4d56b84c5183f90aba42c9a3453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714179/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714179/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1604,4024,27923,27924,27925,53791,53793</link.rule.ids><linktorsrc>$$Uhttps://dx.doi.org/10.1093/ofid/ofx202$$EView_record_in_Oxford_University_Press$$FView_record_in_$$GOxford_University_Press</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29226168$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimmerman, Ofer</creatorcontrib><creatorcontrib>Rösler, Berenice</creatorcontrib><creatorcontrib>Zerbe, Christa S</creatorcontrib><creatorcontrib>Rosen, Lindsey B</creatorcontrib><creatorcontrib>Hsu, Amy P</creatorcontrib><creatorcontrib>Uzel, Gulbu</creatorcontrib><creatorcontrib>Freeman, Alexandra F</creatorcontrib><creatorcontrib>Sampaio, Elizabeth P</creatorcontrib><creatorcontrib>Rosenzwieg, Sergio D</creatorcontrib><creatorcontrib>Kuehn, Hye Sun</creatorcontrib><creatorcontrib>Kim, Tiffany</creatorcontrib><creatorcontrib>Brooks, Kristina M</creatorcontrib><creatorcontrib>Kumar, Parag</creatorcontrib><creatorcontrib>Wang, Xiaowen</creatorcontrib><creatorcontrib>Netea, Mihai G</creatorcontrib><creatorcontrib>van de Veerdonk, Frank L</creatorcontrib><creatorcontrib>Holland, Steven M</creatorcontrib><title>Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease</title><title>Open forum infectious diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>Abstract
Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.</description><subject>Brief Report</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kcFLwzAUxoMobsydvEtOIkg1SZu0uQhjuikMBts8hzRNZ7RLZtOO-d_b2Tnmxct7D74f33u8D4BLjO4w4uG9y03WlC1B5AR0SUiSIOE0Pj2aO6Dv_TtCCGNEUczPQYdwQhhmSRdMZ8Z_eOhyOKu3rjCVsSaFxsL5YrDAcCyNDVwejGqrKuNsMPDeKSMrncG53uhSw0ZaygI-Gq-l1xfgLJeF1_1974HX0dNi-BxMpuOX4WASqChOqiBkkqQ8ozpKGSIkQ4wSxHKEGUaI8IxTkiY6yihLk0hRnIQ5RzKVEVFchhENe-Ch9V3X6UpnStuqlIVYl2Ylyy_hpBF_FWvexNJtBI1xhGPeGNzsDUr3WWtfiZXxSheFtNrVXmAeU8pZ_LPrtkVV6bwvdX5Yg5HYpSB2KYg2hYa-Or7swP7-vAGuW8DV63-dvgFqNJBi</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Zimmerman, Ofer</creator><creator>Rösler, Berenice</creator><creator>Zerbe, Christa S</creator><creator>Rosen, Lindsey B</creator><creator>Hsu, Amy P</creator><creator>Uzel, Gulbu</creator><creator>Freeman, Alexandra F</creator><creator>Sampaio, Elizabeth P</creator><creator>Rosenzwieg, Sergio D</creator><creator>Kuehn, Hye Sun</creator><creator>Kim, Tiffany</creator><creator>Brooks, Kristina M</creator><creator>Kumar, Parag</creator><creator>Wang, Xiaowen</creator><creator>Netea, Mihai G</creator><creator>van de Veerdonk, Frank L</creator><creator>Holland, Steven M</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2017</creationdate><title>Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease</title><author>Zimmerman, Ofer ; Rösler, Berenice ; Zerbe, Christa S ; Rosen, Lindsey B ; Hsu, Amy P ; Uzel, Gulbu ; Freeman, Alexandra F ; Sampaio, Elizabeth P ; Rosenzwieg, Sergio D ; Kuehn, Hye Sun ; Kim, Tiffany ; Brooks, Kristina M ; Kumar, Parag ; Wang, Xiaowen ; Netea, Mihai G ; van de Veerdonk, Frank L ; Holland, Steven M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c478t-36a2b9d5e4b6022d065206f01610029d952b8e4d56b84c5183f90aba42c9a3453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Brief Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimmerman, Ofer</creatorcontrib><creatorcontrib>Rösler, Berenice</creatorcontrib><creatorcontrib>Zerbe, Christa S</creatorcontrib><creatorcontrib>Rosen, Lindsey B</creatorcontrib><creatorcontrib>Hsu, Amy P</creatorcontrib><creatorcontrib>Uzel, Gulbu</creatorcontrib><creatorcontrib>Freeman, Alexandra F</creatorcontrib><creatorcontrib>Sampaio, Elizabeth P</creatorcontrib><creatorcontrib>Rosenzwieg, Sergio D</creatorcontrib><creatorcontrib>Kuehn, Hye Sun</creatorcontrib><creatorcontrib>Kim, Tiffany</creatorcontrib><creatorcontrib>Brooks, Kristina M</creatorcontrib><creatorcontrib>Kumar, Parag</creatorcontrib><creatorcontrib>Wang, Xiaowen</creatorcontrib><creatorcontrib>Netea, Mihai G</creatorcontrib><creatorcontrib>van de Veerdonk, Frank L</creatorcontrib><creatorcontrib>Holland, Steven M</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Zimmerman, Ofer</au><au>Rösler, Berenice</au><au>Zerbe, Christa S</au><au>Rosen, Lindsey B</au><au>Hsu, Amy P</au><au>Uzel, Gulbu</au><au>Freeman, Alexandra F</au><au>Sampaio, Elizabeth P</au><au>Rosenzwieg, Sergio D</au><au>Kuehn, Hye Sun</au><au>Kim, Tiffany</au><au>Brooks, Kristina M</au><au>Kumar, Parag</au><au>Wang, Xiaowen</au><au>Netea, Mihai G</au><au>van de Veerdonk, Frank L</au><au>Holland, Steven M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease</atitle><jtitle>Open forum infectious diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2017</date><risdate>2017</risdate><volume>4</volume><issue>4</issue><spage>ofx202</spage><epage>ofx202</epage><pages>ofx202-ofx202</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>Abstract
Heterozygous STAT1 gain-of-function (GOF) mutations are associated with chronic mucocutaneous candidiasis and a broad spectrum of infectious, inflammatory, and vascular manifestations. We describe therapeutic failures with the Janus Kinase (JAK) inhibitor ruxolitinib in 2 STAT1 GOF patients with severe invasive or cutaneous fungal infections.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>29226168</pmid><doi>10.1093/ofid/ofx202</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 2328-8957 |
| ispartof | Open forum infectious diseases, 2017, Vol.4 (4), p.ofx202-ofx202 |
| issn | 2328-8957 2328-8957 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5714179 |
| source | Oxford Journals Open Access Collection |
| subjects | Brief Report |
| title | Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T12%3A23%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_TOX&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risks%20of%20Ruxolitinib%20in%20STAT1%20Gain-of-Function-Associated%20Severe%20Fungal%20Disease&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Zimmerman,%20Ofer&rft.date=2017&rft.volume=4&rft.issue=4&rft.spage=ofx202&rft.epage=ofx202&rft.pages=ofx202-ofx202&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofx202&rft_dat=%3Cproquest_TOX%3E1975596745%3C/proquest_TOX%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1975596745&rft_id=info:pmid/29226168&rft_oup_id=10.1093/ofid/ofx202&rfr_iscdi=true |